Summary
This chapter provides a synopsis of the development of the receptor concept to explain differential tissue distribution and ultimate specificity of drug action. A relationship between available drug concentration and the proportion of receptors occupied was quickly advanced which implied that drug-receptor interactions obey mass action principles, in a manner analogous to enzyme-substrate interactions. However, Clark’s postulate that the extent of receptor occupancy correlated directly with the extent of elicited response did not explain the majority of experimental findings. To explain the frequent observation that a maximal response could be elicited by occupying only a small fraction of the total receptor population, Stephenson postulated that drugs possess varying efficacies, such that a maximal response can be evoked by occupying differing fractions of the receptor population. Black and Leff have offered a quantitative description of occupancy/response relationships that permits calculation of a transducer ratio for comparison of entire dose-response curves in different tissues or following various experimental manipulations, bringing the quantification of practical descriptors to the nonlinear occupancy-response relationships first introduced by Stephenson. Allosteric models were proposed to account for anomalous antagonisms as well as nonhyperbolic dose-response relationships alluded to earlier. However, multi-state, rather than two-state, models are necessary to describe the varying orders of potencies of a single agonist at a single receptor in evoking different signal outputs.
Distinguishing among the many molecular models that explain how receptor occupancy is linked to biological response ultimately requires purification of the receptor and reconstitution with its purified “effector system,” be it ion translocation or modulation of enzymatic activities. Rigorous characterization of the receptor-response system in the intact target cell is a crucial prerequisite for ultimately understanding the molecular basis for the physiological response observed in vivo, as it is only to the extent that the purified and reconstituted assembly mimics the native receptor-response system that the in vitro system can provide unequivocal insights into receptor mechanisms. Chapter 2 summarizes available methods for determining receptor specificity, the affinity of the putative receptor for its specific agonist, partial agonist, and antagonist agents based on measurements of receptor-mediated response.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Albert, A. (1979) Chemotherapy: History and principles. In Selective Toxicity (6th ed.), Chapman and Hall (eds.). New York: John Wiley and Sons, pp. 182–199. (This section of chapter 6 summarized P. Erhlich’s fundamental contributions to chemotherapy and general “receptor” principles.)
Albert, P.R. and Robillard, L. (2002) G protein specificity: traffic direction required. Cell Signal. 14(5):407–418.
Ariëns, E.J. (1954) Affinity and intrinsic activity in the theory of competitive inhibition. Part I. Problems and theory. Arch. Int. Pharmacodyn. 99:32–49.
Ariëns, E.J. (1960) Receptor reserve and threshold phenomena. I. Theory and experiments with autonomic drugs tested on isolated organs. Arch. Int. Pharmacodyn. 127:459–478.
Ariëns, E.J. and deGroot, W.M. (1954) Affinity and intrinsic-activity in the theory of competitive inhibition. III. Homologous decamethonium-derivatives and succinylcholine-esters. Arch. Int. Pharmacodyn. 99:193–205.
Barger, G. and Dale, H.H. (1910) Chemical structure and sympathomimetic action of amines. J. Physiol. 41:19–59.
Berg., K.A., Maayani, S., Goldfarb, J., Scaramellini, C., Leff, P. and Clarke, W.P. (1998) Effector Pathway-Dependent Relative Effficacy at Serotonin Type 2A and 2C Receptors: Evidence for Agonist-Directed Trafficking of Receptor Stimulus. Mol. Pharm. 54:94–104.
Bernard, C. (1856) Physiological analysis of the properties of the muscular and nervous system by means of curare. Comptes Rendus Acad. de Sci. 43:825–829. Translated and reprinted in Readings in Pharmacology, L. Shuster (ed.). Boston: Little, Brown and Company, pp. 73–81.
Birdsall, N.J., Lazareno, S. and Matsui, H. (1996) Allosteric regulation of muscarinic receptors. Prog. Brain Res. 109:147–151.
Black, J. W. and Leff, P. (1983) Operational models of pharmacological agonism. Proc. Royal Soc. London B. 220:141–162.
Black, J.W., Leff, P. and Shankley, N.P., with an appendix by J. Wood (1985) An operational model of pharmacological agonism: The effect of E/[A] curve shape on agonist dissociation constant estimation. Br. J. Pharm. 84:561–571.
Black, J.W. and Shankley, N.P. (1990) Interpretation of agonist affinity estimations: The question of distributed receptor states. Proc. Royal Soc. London B. 240:503–518.
Changeux, J.-P. and Podleski, T.R. (1968) On the excitability and cooperativity of the electroplax membrane. Proc. Natl. Acad. Sci. USA 59:944–950.
Christopoulos, A. and Kenakin, T.P. (2002) G Protein-Coupled Receptor Allosterism and Complexing. Pharm. Rev. 54:323–374.
Clark, A.J. (1926a) The reaction between acetyl choline and muscle cells. J. Physiol. 61:530–546.
Clark, A.J. (1926b) The antagonism of acetyl choline by atropine. J. Physiol. 61:547–556.
Clark, A.J. (1927) The reaction between acetyl choline and muscle cells. Part II. J. Physiol. 64:123–143.
Clark, A.J. (1937) General Pharmacology. Berlin: Verlag von Julius Springer, pp. 61–98, 176–206 and 215–217.
Clark, A.J. and Raventos, J. (1937) The antagonism of acetylcholine and of quaternary ammonium salts. Quant. J. Exp. Physiol. 26:275–392.
Colquhoun, D. (1973) The relation between classical and cooperative models for drug action. In Drug Receptors, H.P. Rang (ed.). Baltimore: University Park, pp. 149–182.
Dale, H.H. (1914) The action of certain esters and ethers of choline, and their relation to muscarine. J. Pharm. Exp. Ther. 6:174–190.
Erhlich, P. (1913) Chemotherapeutics: Scientific principles, methods and results. Lancet 2:445–451.
Furchgott, R.F. (1955) The pharmacology of vascular smooth muscle. Pharm. Rev. 7:183–235.
Furchgott, R.F. (1964) Receptor mechanisms. Ann. Rev. Pharmacology 4:21–50.
Furchgott, R.F. and Bhadrakom, S. (1953) Reactions of strips of rabbit aorta to epinephrine, isoproterenol, sodium nitrite and other drugs. J. Pharm. Exp. Ther. 108:129–143.
Gaddum, J.H. (1926) The action of adrenalin and ergotamine on the uterus of the rabbit. J. Physiol. 61:141–150.
Gaddum, J.H. (1937) The quantitative effects of antagonistic drugs. J. Physiol. 89:7P–9P.
Gaddum, J.H. (1957) Theories of drug antagonism. Pharm. Rev. 9:211–217.
Gether, U. and Kobilka, B.K. (1998) G Protein-coupled Receptors. II. Mechanism of Agonist Activation. J. Biol. Chem. 273(29):17979–17982.
Ghanouni, P., Bryczynski, Z., Steenhuis, J.J., Lee, T.W., Farrens, D.L., Lakowicz, J.R. and Kobilka, B.K. (2001) Functionally Different Agonists Induce Distinct Conformations in the G Protein Coupling Domain of the β2 Adrenergic Receptor. J. Biol. Chem. 276(27):24433–24436.
Gilchrist, A., Li, A. and Hamm, H.E. (2002) Design and use of C-terminal minigene vectors for studying role of heterotrimeric G proteins. Methods Enzymol. 344:58–69.
Goldstein, A., Aronow, L. and Kalman, S.M. (1974) Principles of Drug Action: The Basis of Pharmacology (2nd ed.). New York: John Wiley and Sons, pp. 82–111.
Hall, D.A. (2000) Modeling the Functional Effects of Allosteric Modulators at Pharmacological Receptors: An Extension of the Two-State Model of Receptor Activation. Mol. Pharm. 58:1412–1423.
Karlin, A. (1967) On the application of a “plausible model” of allosteric proteins to the receptor of acetylcholine. J. Theoret. Biol. 16:306–320.
Kenakin, T. (1995) Agonist-receptor efficacy II: agonist trafficking of receptor signals. TiPS 16:232–238.
Kenakin, T. (2004) Principles: Receptor Theory in Pharmacology. Trends Pharm. Sci. 25:186–192.
Kobilka, B. (2004) Agonist binding: a multi-step process. Mol. Pharm. 65:1060–1062.
Langley, J.N. (1878) On the physiology of the salivary secretion. Part II. On the mutual antagonism of atropin and pilocarpin, having especial reference to their relations in the submaxillary gland of the cat. J. Physiol. 1:339–369.
Langley, J.N. (1909) On the contraction of muscle, chiefly in relation to the presence of “receptive” substances. Part IV. The effect of curare and of some other substances on the nicotine response of the sartorius and gastrocnemius muscles of the frog. J. Physiol. 39:235–295.
Leff, P., Scaramellini, C., Law, C. and McKechnie, K. (1997) A three-state receptor model of agonist action. TiPS 18(10):355–362.
Liapakis, G., Chan, W.C., Papdokostaki, M. and Javtch, J.A. (2004) Synergistic contributions of the functional groups of epinephrine to its affinity and efficacy at the β2 adrenergic receptor. Mol. Pharm. 65:1181–1190.
Lohse, M.J., Benovic, J.L., Caron, M.G. and Lefkowitz, R.J. (1990) Multiple pathways of rapid β2-adrenergic receptor desensitization: Delineation with specific inhibitors. J. Biol. Chem. 265(6):3202–3211, especially appendix pp. 3210–3211.
Monod, J., Wyman, J. and Changeux, J.-P. (1965) On the nature of allosteric transitions: A plausible model. J. Mol. Biol. 12:88–118.
Neubig, R.R., Spedding, M., Kenakin, T. and Christopoulos, A. (2003) Update on Terms and Symbols in Quantitative Pharmacology. NC-IUPHAR XXXVIII 55:597–606.
Nickerson, M. (1956) Receptor occupancy and tissue response. Nature 78:697–698.
Paton, W.D.M. (1961) A theory of drug action based on the rate of drug-receptor combination. Proc. Royal Soc. London B. 154:21–69.
Perez, D.M., Hwa, J., Gaivin, R., Mathur, M., Brown, F. and Graham, R.M. (1996) Constitutive activation of a single effector pathway: evidence for multiple activation sites of a G protein-coupled receptor. Mol. Pharmacol. 49:112–122.
Stephenson, R.P. (1956) A modification of receptor theory. Br. J. Pharm. 11:379–393.
Seifert, R. and Wenzel-Seifert, K. (2002) Constitutive activity of G protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch. Pharmacol. 366(5):381–416.
Seifert, R., Wenzel-Seifert, K., Gether, U. and Kobilka, B.K. (2001) Functional Differences between full and Partial Agonists: Evidence for Ligand-Specific Receptor Conformations. J. Pharm. & Exp. Ther. 297:1218–1226.
Spengler, D., Waeber, C., Pantaloni, C., Holsboer, F., Bockaert, J., Seeberg, P.H. and Journot, L. (1993) Differential signal transduction by five splice variants of the PACAP receptor. Nature 365:170–175.
Stokes, G.G. (1864) On the Reduction and Oxidation of the Colouring Matter of the Blood. Proc. Roy. Soc. London 13:355–364.
Tan, C.M. and Limbird, L.E. (2003) Heterozygous α2A-adrenergic receptor mice unveil unique therapeutic benefits of partial agonists. Proc. Natl. Acad. Sci. USA 99(19):12471–12476.
Thron, C.D. and Waud, D.R. (1968) The rate of action of atropine. J. Pharm. Exp. Ther. 160:91–105.
Van Rossum, J.M. and Ariëns, E.J. (1962) Receptor reserve and threshold phenomena. II. Theories on drug-action and a quantitative approach to spare receptors and threshold values. Arch. Int. Pharmacodyn. 136:385–413.
Whaley, B.S., Yuan, N., Birnbaumer, L., Clark, R.B. and Barber, R. (1994) Differential expression of the beta-adrenergic receptor modifies agonist stimulation of adenylyl cyclase: a quantitative evaluation. Mol. Pharmacol. 45(3):481–489.
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
(2005). Introduction to Receptor Theory. In: Cell Surface Receptors. Springer, Boston, MA. https://doi.org/10.1007/0-387-23080-7_1
Download citation
DOI: https://doi.org/10.1007/0-387-23080-7_1
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-23069-6
Online ISBN: 978-0-387-23080-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)